The global preimplantation genetic testing market size was valued at USD 0.91 billion in 2025 and is projected to grow from USD 0.99 billion in 2026 to USD 2.01 billion by 2034 at a CAGR of 9.23% during the forecast period 2026-2034. North America dominated the preimplantation genetic testing market with a market share of 42.5% in 2025.
Preimplantation genetic testing (PGT) is increasingly integral to assisted reproductive technologies (ART), offering early detection of genetic abnormalities in embryos before implantation. Rising infertility rates, advancements in genetic screening technologies, and growing awareness of hereditary diseases drive the market's expansion. Couples seeking to prevent transmission of genetic disorders are turning to PGT as a proactive measure. Technological innovations, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), have enhanced the accuracy and efficiency of PGT, making it more accessible and reliable.
Download a Free Sample To learn more about this report,
Integration of AI and Automation in PGT
The integration of artificial intelligence (AI) and automation in preimplantation genetic testing is transforming the field by improving diagnostic precision and laboratory efficiency. AI-driven algorithms enable more sophisticated analysis of complex genetic data, enhancing the accuracy of detecting chromosomal abnormalities and genetic mutations. Automation reduces manual labour and human error by streamlining workflows such as sample preparation, embryo imaging, and data reporting. For example, AI-assisted embryo imaging platforms use deep learning to evaluate embryo viability, supporting embryologists in selecting embryos with the highest implantation potential, thereby improving IVF success rates. Companies like CooperSurgical have recently introduced AI-powered PGT platforms, enabling faster turnaround and better diagnostic outcomes.
As AI and automation evolve, they will continue redefining reproductive genetics standards by delivering personalised, efficient testing solutions globally.
Rising Prevalence of Genetic Disorders
The growing global prevalence of genetic disorders is a key factor propelling demand for preimplantation genetic testing. According to the WHO, millions of people worldwide are affected by inherited conditions such as cystic fibrosis, thalassemia, sickle cell anaemia, and Tay-Sachs disease. PGT offers a preventive measure by enabling prospective parents to screen embryos for genetic mutations before implantation, significantly reducing the risk of transmitting hereditary diseases. Increased public awareness of genetic counselling and testing options has empowered families to make informed reproductive decisions.
This rising demand is expected to continue driving the global PGT market forward.
High treatment costs and uncertain clinical benefits remain important restraints for the PGT market. PGT is performed alongside IVF, adding laboratory and testing expenses that may not be fully covered by insurance. Clinical evidence is also mixed for PGT-A. ASRM's 2024 committee opinion states that recent multicenter randomized trials found similar overall pregnancy outcomes with PGT-A and conventional IVF in women with available blastocysts. Testing also involves biopsy of a small group of cells, meaning results may not always represent the entire embryo. Mosaic findings can be difficult to interpret, and different laboratories may use different thresholds and reporting methods. These issues can make patients and doctors cautious about routine testing.
A major opportunity lies in improving the accuracy and interpretation of embryo genetic testing. NGS-based testing is becoming more sophisticated, while research into mosaic embryos could help clinics make better transfer decisions. ASRM notes that mosaic embryos can sometimes implant and result in apparently euploid offspring, highlighting the need for improved classification and genetic counseling. Another opportunity is the expansion of PGT for families with known inherited genetic conditions, where testing has a clearer clinical purpose than universal PGT-A screening. The U.S. ART sector also provides a large potential patient base: CDC data show 251,542 unique patients underwent ART treatment across 457 reporting clinics in 2022. Better access, lower testing costs, and improved insurance coverage could further support adoption.
The PGT market faces challenges involving scientific accuracy, clinical interpretation, regulation, and patient expectations. One major issue is mosaicism: a biopsy may show mixed chromosomal results, but it does not always predict the genetic status of the entire embryo. ASRM states that mosaic diagnoses can vary according to the NGS platform, laboratory thresholds, software, and interpretation methods. The organization also says there is currently no evidence-based method to precisely predict outcomes for individual mosaic embryos. Another challenge is proving when PGT-A genuinely improves outcomes, as ASRM's 2024 guidance found no established benefit as a universal screening test. These uncertainties increase the need for standardized testing, transparent reporting, and qualified genetic counseling.
Request Customizationto receive a tailored report.
Preimplantation Genetic Screening (PGS) held the largest share of the preimplantation genetic testing market, accounting for 61.8%, with a market value of $0.56 billion and a CAGR of 10.9%. Its leading position reflects strong demand for screening embryos for chromosomal abnormalities before implantation during IVF treatment. Growing awareness of embryo selection, increasing use of assisted reproductive technologies, and the rising number of patients seeking improved IVF outcomes are supporting demand for PGS. Advances in genetic testing technologies are also making embryo screening more efficient and helping fertility specialists make more informed decisions during treatment.
Preimplantation Genetic Diagnosis (PGD) remains an important procedure for families with a known risk of passing inherited genetic disorders to their children. Unlike broader chromosomal screening, PGD is primarily used to identify specific genetic conditions in embryos before transfer. Its use is supported by growing awareness of inherited diseases and improvements in molecular testing methods. Genetic counseling and improved access to fertility services are also helping more patients understand the potential role of PGD. The procedure is particularly relevant for couples with a family history of genetic disorders who want to reduce the likelihood of transmitting specific conditions.
Reagents and Consumables represented the fastest-growing product segment, recording a CAGR of 11.2%, while holding a market share of 58.6% and reaching a market value of $0.53 billion. The segment's strong position is supported by the recurring need for laboratory materials used throughout embryo biopsy, DNA extraction, amplification, and genetic analysis. Increasing IVF activity and the wider adoption of genetic testing are creating consistent demand for these products. Improvements in testing workflows and the growing use of advanced sequencing methods are also encouraging laboratories to adopt more specialized reagents and consumables for accurate embryo analysis.
Instruments and software play complementary roles in supporting the PGT workflow. Advanced laboratory instruments are essential for sample preparation, amplification, sequencing, and other testing processes, while software helps laboratories manage genetic data and interpret complex results. The adoption of automated laboratory systems is improving workflow efficiency and reducing manual intervention. At the same time, software solutions are becoming increasingly important as genetic datasets become more complex. Better data management, automated analysis, and integration with laboratory information systems are expected to support the wider use of digital tools across fertility clinics and genetic testing laboratories.
Next-Generation Sequencing (NGS) was the leading technology segment, accounting for 47.9% of the market and generating a market value of $0.44 billion. It is also projected to grow at the fastest CAGR of 12.4%. NGS is gaining traction because it can analyze large amounts of genetic information with high sensitivity and support detailed chromosome assessment. Its growing use in embryo testing is being encouraged by advances in sequencing platforms, improved laboratory workflows, and increasing demand for more comprehensive genetic analysis. The technology is becoming an important part of modern PGT services as fertility laboratories seek more advanced approaches to evaluate embryo genetic characteristics.
Polymerase Chain Reaction (PCR) continues to have an established role in preimplantation genetic testing, particularly for detecting specific genetic mutations and inherited disorders. Its established laboratory infrastructure and ability to deliver targeted genetic analysis make it useful in selected PGT applications. Fluorescent In Situ Hybridisation (FISH) remains relevant in certain chromosome-related testing procedures, although newer technologies have expanded the range of available testing options. Other technologies also contribute to the market by supporting specialized genetic analysis and laboratory applications. Together, these methods provide fertility specialists with different testing approaches depending on the patient's genetic risk, clinical requirements, and laboratory capabilities.
Aneuploidy Screening was the fastest-growing application segment, with a CAGR of 11.4%, while accounting for 27.6% of the market and reaching a value of $0.25 billion. The segment is expanding as fertility clinics increasingly focus on identifying embryos with abnormal chromosome numbers before transfer. Aneuploidy is associated with implantation failure and miscarriage, making chromosome assessment an important consideration in certain IVF cases. Growing use of advanced sequencing technologies, improvements in embryo testing, and increasing demand for personalized fertility treatment are supporting the segment. However, clinical decisions around aneuploidy testing continue to depend on patient characteristics and medical guidance.
Chromosomal abnormalities represent a major application of PGT, with testing helping identify genetic changes that may affect embryo development. Testing for X-linked diseases is particularly relevant for families at risk of passing sex-linked inherited conditions to their children. Embryo testing is also used more broadly to assess genetic characteristics before implantation, while HLA typing serves specialized cases where embryo selection may be considered in relation to tissue compatibility. Other applications cover additional genetic conditions and specialized clinical needs. Increasing awareness of inherited disorders and improvements in genetic counseling are helping patients better understand these testing options.
Fertility Centres represented the fastest-growing end-user segment, recording a CAGR of 11.5%, while holding the largest market share of 48.7% and reaching a market value of $0.44 billion. Their leading position reflects the close connection between PGT and IVF treatment, as fertility centres provide the clinical infrastructure needed for embryo creation, biopsy, testing coordination, and embryo transfer. Growing demand for assisted reproduction and increasing interest in personalized fertility care are supporting the use of PGT services in these facilities. Technological improvements and partnerships between fertility clinics and specialized genetic laboratories are also helping expand access to advanced embryo testing.
Hospitals remain important users of PGT services because they often provide integrated fertility, reproductive medicine, and genetic counseling programs. Diagnostic centres support the market by providing specialized genetic analysis and laboratory testing services, often working with fertility clinics to process embryo samples. Research centres and academic laboratories contribute to technological development, clinical research, and the evaluation of new testing approaches. Their work is important for improving the understanding of embryo genetics and developing more accurate testing methods. Together, these end users create a broader ecosystem that supports clinical application, laboratory analysis, research, and innovation in preimplantation genetic testing.
Speak to an Analystto discuss market opportunities.
North America held the largest share of the global preimplantation genetic testing market in 2025, accounting for 42.5%, with a market value of $0.39 billion. The region is supported by advanced IVF infrastructure, established fertility clinics, and widespread access to genetic testing services. The market is projected to grow at a 10.2% CAGR during the forecast period. The United States and Canada are key contributors, supported by growing demand for personalized reproductive care and increasing awareness of inherited genetic disorders. Technological advancements in embryo testing and improved laboratory capabilities are also strengthening the region's market position.
The United States is a major contributor to the North American market due to its advanced IVF infrastructure and large network of fertility clinics. Growing demand for personalized reproductive care and genetic testing is supporting PGT adoption. The country also has strong biotechnology and genetic testing industries, encouraging innovation in sequencing and embryo analysis. However, treatment costs and insurance coverage remain important factors influencing patient access.
Canada's PGT market is supported by its developed healthcare system and growing access to fertility services. Fertility clinics are increasingly using genetic counseling and embryo testing for suitable IVF patients. Demand is driven by greater awareness of inherited genetic conditions and interest in reproductive planning. Regional differences in healthcare funding and access to fertility treatment can influence adoption across the country.
Asia Pacific is the fastest-growing regional market, with a 12.1% CAGR during the forecast period. The region held a 20.6% market share in 2025, representing a market value of $0.19 billion. Growth is supported by increasing IVF adoption, expanding fertility clinics, improving healthcare infrastructure, and rising awareness of genetic testing. Japan and China are major contributors to regional development. Advances in reproductive medicine, increasing healthcare investment, and better access to specialized genetic laboratories are creating new opportunities. The growing focus on personalized fertility treatment is also expected to strengthen demand for PGT services across the region.
Japan has an advanced healthcare system and strong expertise in reproductive medicine, supporting the adoption of PGT. Fertility-related challenges and growing interest in assisted reproduction are creating demand for advanced embryo testing. The country also has a strong research environment supporting innovation in genetic testing. However, regulatory and ethical considerations remain important factors influencing the use of PGT in clinical practice.
China is a major growth market supported by its large population, increasing demand for assisted reproduction, and expanding fertility services. Greater awareness of inherited genetic conditions is encouraging interest in embryo testing. Improvements in sequencing technologies and laboratory capabilities are also supporting market development. Regulatory requirements surrounding assisted reproduction and genetic testing remain important considerations for providers operating in the country.
Europe accounted for 28.4% of the global preimplantation genetic testing market in 2025, with a market value of $0.26 billion. The region is expected to grow at a 10.4% CAGR during the forecast period. Established fertility clinics, advanced genetic laboratories, and developed healthcare systems support market growth. Germany and the United Kingdom are key markets, driven by demand for reproductive genetic services and greater awareness of inherited disorders. However, differences in regulations, ethical guidelines, and access to fertility treatment across countries can influence the adoption of PGT services.
Germany benefits from advanced healthcare infrastructure and specialized reproductive medicine services. Demand for PGT is supported by families seeking to reduce the risk of inherited genetic conditions. The country also has a strong medical research ecosystem supporting genetic testing advancements. However, strict legal and ethical regulations surrounding embryo testing play an important role in determining how PGT services are used.
The UK has an established fertility treatment sector and strong expertise in reproductive genetics. PGT is used for appropriate clinical indications, particularly when families face a known risk of inherited genetic disorders. The country's research capabilities also support innovation in embryo testing. Regulatory oversight remains an important part of the market, while growing interest in personalized reproductive care continues to support demand.
Latin America represented 5.1% of the global preimplantation genetic testing market in 2025, reaching a market value of $0.05 billion. The region is projected to grow at a 9.7% CAGR during the forecast period. Brazil is a key market, supported by expanding fertility clinics and growing use of assisted reproductive technologies. Increasing awareness of genetic testing is creating additional demand. However, differences in healthcare infrastructure, treatment affordability, and access to specialized laboratories continue to influence the availability of PGT services across the region.
Brazil is an important market for reproductive medicine in Latin America, supported by a growing network of fertility clinics and specialists. Demand for PGT is increasing among patients undergoing IVF and families concerned about inherited genetic conditions. Improvements in laboratory capabilities are supporting wider access to genetic testing. However, treatment costs and differences in access to specialized fertility services remain challenges for broader adoption.
The Middle East and Africa accounted for 3.4% of the global preimplantation genetic testing market in 2025, with a market value of $0.03 billion. The region is expected to grow at a 8.9% CAGR during the forecast period. Growth is supported by healthcare investment, improving fertility services, and increasing awareness of genetic diseases. The UAE is an important market due to its modern healthcare infrastructure and specialized medical facilities. However, limited access to advanced laboratories and differences in healthcare development across countries may restrict wider adoption.
The UAE is emerging as an important PGT market in the Middle East, supported by modern healthcare infrastructure and growing investment in specialized medical services. The country has a developing fertility treatment sector and attracts patients seeking advanced reproductive care. Increasing awareness of inherited genetic conditions is supporting demand for PGT. Healthcare modernization and medical tourism may create further opportunities, although treatment costs and regulatory requirements remain important considerations.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com